HeadInvest LLC’s Neurocrine Biosciences NBIX Stock Holding History

HeadInvest LLC’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-250	Closed	-$27.9K	–	516
2023 Q3	$27.9K	Buy	+250	New	+$26.3K	0.01%	421

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

HeadInvest LLC's NBIX Position: Q4 2023 in Review

HeadInvest LLC sold out of Neurocrine Biosciences (NBIX) in Q4 2023, closing a stake of 250 shares — an estimated $27.9K sold.

HeadInvest LLC first reported a position in NBIX in Q3 2023 and held it in 1 quarter. The position peaked at $27.9K in Q3 2023. 554 funds tracked by Wall St. Rank hold NBIX as of Q4 2023.

HeadInvest LLC reported no remaining Neurocrine Biosciences position as of Q4 2023 after selling out during the quarter.
HeadInvest LLC sold 250 Neurocrine Biosciences shares in Q4 2023, an estimated $27.9K.
HeadInvest LLC first reported a position in Neurocrine Biosciences in Q3 2023 and held it in 1 quarter.
HeadInvest LLC's Neurocrine Biosciences position peaked at $27.9K in Q3 2023.
554 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2023.

Based on HeadInvest LLC's 13F filing for Q4 2023, filed 12 Feb 2024.